Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.
Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.
The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.
Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.
VolitionRx Limited (VNRX) has announced the CE marking of its Nu.Q® NETs test for the detection and evaluation of NETosis, allowing clinical use in over 27 European countries. This test can detect NETosis through routine blood tests, offering significant commercial potential with a Total Addressable Market of approximately $6.5 billion for sepsis in Europe. The company expects to start commercialization in the first half of 2023. The test aims to support physicians in managing diseases associated with NETosis, including sepsis and COVID-19.
VolitionRx Limited (VNRX) reported financial results for Q1 2022, highlighting a net loss of $7.7 million compared to $6.1 million in Q1 2021. Cash reserves increased to $23.7 million, boosted by a $10 million milestone payment from Heska Corporation following a major licensing agreement for the Nu.Q® Vet Cancer Screening Test. The company is also expanding its operations with new hires and recent product launches in Singapore. Upcoming milestones include further licensing agreements, sales of test components, and clinical studies.
VolitionRx Limited (NYSE AMERICAN: VNRX) will hold a conference call on May 12, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and business updates. The call will feature CEO Cameron Reynolds and other executives. Additionally, a Capital Markets Day is scheduled for May 13, 2022, at 10:00 a.m. ET at the New York Stock Exchange. These events aim to provide insight into recent developments and future milestones within the company.
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a hybrid Capital Markets Day on May 13, 2022, at 10 a.m. Eastern Time. The event, held at Siebert Hall, NYSE, will feature the executive team providing strategic updates and discussing key growth drivers. Topics include veterinary market opportunities, clinical results, and financial metrics. Attendees can register for virtual participation. Presentations will be available on the company’s website, with a replay offered post-event.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the launch of its Nu.Q® Vet Cancer Test in Asia via distributor SAGE Healthcare on April 25, 2022. Following their appointment in December 2021, SAGE has commenced marketing the test, which aims to facilitate early cancer detection in pets. CEO Dr. Jasmine Kway emphasized the growing pet ownership in Asia, presenting a significant market opportunity for the test. SAGE plans to expand the product's availability to other Asian markets.
VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed Sharon Ballesteros as the U.S. Head of Quality and Development Process, effective April 4, 2022. Ballesteros brings over 20 years of experience from her previous roles at Siemens Health Diagnostics and GRAIL. This move supports Volition's expansion efforts in California, including a new 6,000 ft lab in Carlsbad. The company aims to enhance its regulatory processes to commercialize its Nu.Q® diagnostic products for various diseases. A warrant for 54,000 shares at $3.05 per share was granted to Ballesteros as part of her appointment.
VolitionRx Limited (NYSE AMERICAN: VNRX) provided a business update on March 30, 2022, announcing a global licensing deal with Heska Corporation for the Nu.Q® Vet Cancer Screening Test. This deal includes a $10 million upfront payment and potential milestone payments of up to $18 million. Volition reported a net loss of $27 million for 2021, largely due to non-cash items and increased staffing costs, with cash reserves totaling $20.6 million. The company continues to advance its product development and has a total addressable market estimated at $70 billion.
VolitionRx Limited (NYSE AMERICAN: VNRX) has entered an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) to market its Nu.Q® Vet Cancer Screening Test for companion animals. This deal includes a $10 million upfront payment and up to $18 million for milestone achievements. The test aims to enhance early cancer detection in dogs and cats, targeting a global market estimated at $11 billion. Administrating this test will be facilitated through Heska's proprietary analyzers, making it accessible and affordable for veterinarians.
Heska Corporation (NASDAQ: HSKA) has entered an exclusive global supply and licensing agreement with VolitionRx Limited (NYSE AMERICAN: VNRX) to commercialize the Nu.Q® Vet Cancer Screening Test for companion animals. This test aims to provide veterinarians with the ability to screen pets for cancer at the point of care. With an estimated $11 billion market for canine and feline cancer screening, this innovative solution is expected to greatly enhance early detection and treatment for pets, benefiting both healthcare outcomes and pet owners.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a conference call scheduled for March 31, 2022, at 08:00 a.m. Eastern time to discuss its full fiscal year 2021 financial and operating results and provide a business update. The call will feature CEO Cameron Reynolds and other executives discussing recent developments and ongoing clinical trials. Investors can access a live audio webcast on the company’s investor relations page. A replay of the call will be available until April 14, 2022.